Clinical Trials Browser

tislelizumab × Lymphoid × 1 year × Clear all

NCT04539444 2026-06-02

A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma

Phase 2 Completed

Lymphoma, Non-Hodgkin, Recurrence

NCT07502768 2026-03-31

EpiRev-NKT

Phase 1/2 Not yet recruiting

Recurrence, Lymphoma, Extranodal NK-T-Cell

NCT05502250 2026-03-06

HOVON164HL

Phase 2 Active not recruiting

Hodgkin Disease

NCT04282018 2026-02-20

Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab

Phase 1/2 Completed

97 enrolled 43 charts

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT07418190 2026-02-18

Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma

Phase 2 Recruiting

Lymphoma, Follicular

NCT04425070 2026-01-05

TOUCH

Phase 1/2 Terminated

Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

NCT05977673 2025-12-08

FIL_Tisle-HL

Phase 2 Recruiting

Hodgkin Disease, Lymphoma

NCT04170283 2025-10-21

Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies

Phase 3 Active not recruiting

B-cell Malignancies

NCT05267054 2025-09-15

Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab

Phase 1/2 Completed

53 enrolled 17 charts

Lymphoma, Neoplasms, Lymphoma, Large B-Cell, Diffuse

NCT07031700 2025-06-22

A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL

Phase 2 Not yet recruiting

Lymphoma, Follicular